mouse flt3l elisa kit  (Proteintech)

Journal: Signal Transduction and Targeted Therapy

Article Title: Oncolytic adenovirus delivery of neoantigens sensitizes low-mutation tumors to anti-PD-1 therapy and prevents metastasis

doi: 10.1038/s41392-025-02511-5

Figure Lengend Snippet: Construction and in vivo validation of NeoViron. a ‒ d C57BL/6 mice inoculated with mICCN-4 or Hep53.4 cells were treated with PBS, vector or AdSVP-Flt3L. For the mICCN-4 model, treatment was initiated on day 8, with intratumoral injections of 1 × 10⁸ pfu OAV administered every other day for a total of five doses. For Hep53.4 tumors, treatment commenced on Day 6 with intratumoral injections of 2 × 10⁸ pfu OAV every other day for five doses. a , b Left, tumor images at the end point. Middle, tumor growth curves ( n = 6 mice per group). c , d CD103+ cDC1s were examined by flow cytometry ( c ) or immunofluorescence staining (MHC II+ CD103+ cells) ( d ). e Design of NeoViron, coexpressing neoantigens and Flt3L. f – h C57BL/6 mice inoculated with mICCN-4 were treated with PBS or 1 × 10⁸ pfu OAV (vector, AdSVP-NAg mICC , AdSVP-Flt3L or NeoViron) from Day 8 every other day for a total of five doses. f Left, experimental schematic. Middle, tumor images at the end point. Right, tumor growth curves ( n = 6 mice per group). g Percentages of PD1+ GZMB+ CD8+ T cells and PD1+ GZMB- CD8+ T cells infiltrating the tumor tissues of each group. h Representative immunofluorescence images of GZMB+ CD8+ T cells in tumor tissues. The data are shown as the means ± SDs ( a – g ) and are representative of two ( a – h ) independent experiments. Significance was calculated via one-way ANOVA ( a – c , g ) or two-way ANOVA ( a , b , f ). * P < 0.05, ** P < 0.01, *** P < 0.001. ns not significant

Article Snippet: One hundred milligrams of tumor tissue were finely sliced and incubated at 37 °C in 200 μL of PBS for 2 h. The supernatants were then collected and analyzed via a mouse Flt3L ELISA Kit (Proteintech, USA).

Techniques: In Vivo, Biomarker Discovery, Plasmid Preparation, Flow Cytometry, Immunofluorescence, Staining, Immunopeptidomics

Journal: Signal Transduction and Targeted Therapy

Article Title: Oncolytic adenovirus delivery of neoantigens sensitizes low-mutation tumors to anti-PD-1 therapy and prevents metastasis

doi: 10.1038/s41392-025-02511-5

Figure Lengend Snippet: NeoViron-induced CD8+ Trm cells prevent tumor metastasis. a ‒ g C57BL/6 mice inoculated with mICCN-4 or Hep53.4 cells were treated with PBS, vector or NeoViron/AdSVP-NAg Hep + AdSVP-Flt3L 5 times, followed by tumor excision on day 16. One week later, liver/lung metastasis models were established by injecting tumor cells via the spleen/tail vein. a , d Experimental schematic. b , e Tumor area of liver metastases and counts of lung metastases analyzed by ImageJ. c , f HE-stained images of liver and lung metastases at the end of the experiment. g Multiplex immunofluorescence images showing CD8+ Trm cells in liver and lung metastases. The data are shown as the means ± SDs ( b , e ) and are representative of two independent experiments ( a – h ). Significance was calculated via the Kruskal‒Wallis test ( b , e ). * P < 0.05, *** P < 0.001. ns not significant

Article Snippet: One hundred milligrams of tumor tissue were finely sliced and incubated at 37 °C in 200 μL of PBS for 2 h. The supernatants were then collected and analyzed via a mouse Flt3L ELISA Kit (Proteintech, USA).

Techniques: Plasmid Preparation, Staining, Multiplex Assay, Immunofluorescence